Details about Philippe GORRY

Access statistics for papers by Philippe GORRY.

Last updated 2022-12-01. Update your information in the RePEc Author Service.

Short-id: pgo436

Working Papers

2022

1. Drug shortages, APIs supply & Pharma Global Value Chain
   Post-Print, HAL

2021

2. Beyond health security dependencies. Rethinking public health and industrial policies construction
   (Seguridad sanitaria bajo dependencia. Una construcción política a repensar)
   Post-Print, HAL

2020

3. Assessment of generic competition for Orphan Drugs marketed in the US (1993-2019)
   Post-Print, HAL
4. Impact de la législation européenne des médicaments orphelins sur le marché global du médicament
   Post-Print, HAL
5. Le statut de médicament orphelin est un signal positif pour les investisseurs lors de l'introduction en bourse des sociétés de biotechnologie
   Post-Print, HAL
6. Médicaments orphelins et maladies rares sur Twitter
   Post-Print, HAL
7. Pourquoi les prix des traitements contre les maladies rares deviennent fous ?
   Post-Print, HAL

2019

8. Atelier "Accès à l'innovation"
   Post-Print, HAL
9. Drug Safety scientometrics overview highlights public health issues
   Post-Print, HAL
10. Global overview of patenting landscape in unmanned aerial vehicles
    Post-Print, HAL
11. Market Valuation of FDA Orphan Drug Regulatory Events
    Post-Print, HAL View citations (2)
12. R&D incentives and innovation spillovers: evidence from the European orphan drug regulation
    Post-Print, HAL

2018

13. Delayed Recognition in Science: Different Causes of Sleeping and Awakening of Discoveries
    Post-Print, HAL
14. Does Orphan Drug market exclusivity incentive sustains drug development for rare diseases ?
    Post-Print, HAL
15. Exploring the historical roots of mesenchymal stem cell research using reference publication year spectroscopy
    Post-Print, HAL
16. Impact of Health Technology Assessment on Innovation Diffusion: the case of techniques in Interventional Radiology
    Post-Print, HAL
17. Naming institution after neologism as marker of the institutionalization of new discipline
    Post-Print, HAL
18. Orphan Drug Market Exclusivity Extension versus Patent Monopoly
    Post-Print, HAL

2017

19. Angiogenesis inhibitors drug pipeline landscape
    Post-Print, HAL
20. Empirical Economic Analysis of Orphan Drug Innovation
    Post-Print, HAL
    Also in Post-Print, HAL (2016)
    Post-Print, HAL (2016)
21. Evolution des prescriptions de médicaments orphelins en cancérologie: en France, et à l’échelle d’un établissement hospitalier
    Post-Print, HAL
    Also in Post-Print, HAL (2016)
22. Neologisms and affiliation name: a bibliometric perspective on the institutionalization of interventional radiology
    Post-Print, HAL
23. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies
    NBER Working Papers, National Bureau of Economic Research, Inc
    Also in Post-Print, HAL (2016)
    Post-Print, HAL (2015)
    See also Chapter Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies, NBER Chapters, National Bureau of Economic Research, Inc (2018) (2018)
24. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies. NBER working paper n° w24021
    Working Papers, HAL
25. Orphan Drug legislation: evaluation of the impact of market exclusivity extension
    Post-Print, HAL
26. Orphan Drugs: Why the US legislation approves more than the EU?
    Post-Print, HAL
27. Science and Technology Indicators of Microalgae-Based Biofuel Research
    Post-Print, HAL
28. Social Recognition of a Medical Innovation: the case of Interventional Radiology in Oncology
    Post-Print, HAL
29. The Dissemination of the Concept of “Interventional Radiology” in Medical and Scientific Literature
    Post-Print, HAL
    Also in Post-Print, HAL (2017)

2016

30. Biodiversity Sustainability of Phytomedicine Research: a 3-dimensions analysis around the North-South divide
    Post-Print, HAL
31. Economie de la santé: les médicaments orphelins
    Post-Print, HAL
32. Empirical Economic Analysis of Orphan Drug Legislation Impact on Innovation
    Post-Print, HAL
    Also in Post-Print, HAL (2016)
33. Health innovation for rare diseases
    Post-Print, HAL View citations (2)
34. Pharma Competitive Intelligence using open source data and visualization tool: towards metrics for drug R&D milestones
    Post-Print, HAL
35. Serendipity and university technology transfer: a case study
    Post-Print, HAL
36. Towards a Patent landscaping of Regenerative Medicine
    Post-Print, HAL View citations (1)
37. Website: orphandrugseconomics.org
    Post-Print, HAL

2015

38. Charles Dotter & the birth of Interventional Radiology: A sleeping beauty with a restless sleep
    Post-Print, HAL
39. Construction of mental health categories
    (La construction des catégories diagnostiques de maladie mentale)
    Post-Print, HAL View citations (1)
40. Diffusion of Interventional Radiology and Health Technology Assessment: the case of radiofrequency treatment in oncology
    Post-Print, HAL
41. Does scientific knowledge play a role in public policies? A contribution of scientometrics to political science: the case of HTA
    Post-Print, HAL
42. Intellectual Property Rights and Traditional Knowledge: to which extend biodiversity is preempted at the global level
    Post-Print, HAL
43. L’histoire de la radiologie interventionnelle: développement et diffusion d’une innovation médicale
    Post-Print, HAL
44. Mapping scientific dynamics in « Regenerative Medicine » research
    Post-Print, HAL
45. Mapping scientific dynamics in « Regenerative Medicine » research, Tissue Engineering Part A, 21, S1
    Post-Print, HAL
46. Medical literature imprinting by pharma ghost writing: a scientometric evaluation
    Post-Print, HAL
47. Naissances de la radiologie interventionnelle. Le rôle de Charles T. Dotter
    Post-Print, HAL

2014

48. Approche quantitative de la diffusion d’un innovation: exemple de la radiologie interventionnelle
    Post-Print, HAL
49. Building an orphan drug market database to enpower decision making by patient organizations & pharma-biotech companies
    Post-Print, HAL
50. Diagnostic prénatal non invasif sur sang maternel & Propriété Intellectuelle: entre éthique de la santé et efficience du marché
    Post-Print, HAL
51. Institutionalizarion of public policies & diffusion of innovation: the case of interventional radiology
    Post-Print, HAL
52. Institutionnalisation des politiques publiques de santé & diffusion de l’innovation médicale
    Post-Print, HAL
53. Les enjeux de la reconnaissance de la radiologie interventionnelle: un travail de recherche interdisciplinaire (sociologie, économie, droit)
    Post-Print, HAL
54. The EU's Government of Pharmaceuticals: Incompleteness Embraced
    Post-Print, HAL
55. Ultrasons focalisés de haute intensité: analyse des dynamiques d’innovations
    Post-Print, HAL

2013

56. A patent landscaping of medicinal plants extracts
    Post-Print, HAL
57. Analyse sectorielle, technologique et économique, du marché des médicaments orphelins
    Post-Print, HAL
58. CH2 Une demande structurée par les prescripteur & CH3 Un système dominé par les firmes multinationales pharmaceutiques
    Post-Print, HAL
59. HTA National Public Policy and Their Socio-Economic Environment: A European Perspective
    Post-Print, HAL
60. Health Technology Assessment Agencies and their economic environment: a European perspective
    Post-Print, HAL
61. The scientific-knowledge based institutionalization of Health Technology Assessment: a bibliometric and network analysis
    Post-Print, HAL

2012

62. Construction politique des marchés et politiques des prix. Le cas de l'industrie pharmaceutique
    Post-Print, HAL
63. Schéma régional de l'enseignement supérieur, de la recherche & de l'innovation
    Post-Print, HAL

2011

64. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS)
    Post-Print, HAL
65. Regulating the drugs market in the EU: the contradiction between safety, innovation and access to care
    Post-Print, HAL

2010

66. Impact of market exclusivity versus IP protection in fostering innovation for rare diseases
    Post-Print, HAL
67. The political construction of orphan drugs market: between innovation & access to care
    Post-Print, HAL

Journal Articles

2021

1. Sécurité sanitaire sous dépendance. Une construction politique à repenser
   (Beyond health security dependencies. Rethinking public health and industrial policies construction)
   Revue de la Régulation - Capitalisme, institutions, pouvoirs, 2021, 29

2018

2. Delayed recognition of Judah Folkman’s hypothesis on tumor angiogenesis: when a Prince awakens a Sleeping Beauty by self-citation
   Scientometrics, 2018, 116, (1), 385-399 View citations (9)

2016

3. “Sleeping beauty” and her restless sleep: Charles Dotter and the birth of interventional radiology
   Scientometrics, 2016, 107, (2), 773-784 View citations (13)

2015

4. La construction des catégories diagnostiques de maladie mentale
   Revue de la Régulation - Capitalisme, institutions, pouvoirs, 2015, 17

Chapters

2018

1. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies
   A chapter in Economic Dimensions of Personalized and Precision Medicine, 2018, pp 305-334
   See also Working Paper Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies, National Bureau of Economic Research, Inc (2017) (2017)